Merck’s latest Keytruda approval isn’t necessarily a huge one for the New Jersey drugmaker when it comes to sales. But it’s a big deal for Pfizer and Merck KGaA, maker of rival drug Bavencio.
Roche’s immuno-oncology rivals are hurtling toward a showdown in previously untreated kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.